Home » Stocks » BXRX

Baudax Bio, Inc. (BXRX)

Stock Price: $1.30 USD -0.03 (-2.26%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.31 +0.01 (0.77%) Jan 15, 7:59 PM
Market Cap 55.43M
Revenue (ttm) 417,000
Net Income (ttm) -66.38M
Shares Out 18.37M
EPS (ttm) -3.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.30
Previous Close $1.33
Change ($) -0.03
Change (%) -2.26%
Day's Open 1.33
Day's Range 1.28 - 1.37
Day's Volume 3,317,364
52-Week Range 0.97 - 9.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today ...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, th...

GlobeNewsWire - 1 month ago

MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today ...

GlobeNewsWire - 1 month ago

ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics ANJESO Found to Provide Superior Pain Relief with Similar or Bett...

Seeking Alpha - 2 months ago

Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

BXRX has been pummeled since the start of the pandemic dropping from the high $7s to the low $1s. In this article, I review the company developments, both negative and positive, that have tran...

GlobeNewsWire - 2 months ago

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report th...

GlobeNewsWire - 2 months ago

ANJESO ® Launch Underway ; Over 50 Institutions have A dded ANJESO to T heir F ormular ies

GlobeNewsWire - 3 months ago

MALVERN, Pa., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation...

GlobeNewsWire - 3 months ago

MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the ...

InvestorPlace - 4 months ago

These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential ap...

Other stocks mentioned: AMRS, LIFE
Seeking Alpha - 4 months ago

Baudax Bio: Discounted Despite Long-Term Prospects

GlobeNewsWire - 4 months ago

MALVERN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has been awa...

GlobeNewsWire - 4 months ago

MALVERN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies,...

Seeking Alpha - 5 months ago

Baudax Bio's (BXRX) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Commenced Commercial Launch of ANJESO ® in the U.S.

GlobeNewsWire - 5 months ago

Effective October 1, 2020, New Code Expected to Expand Reimbursement Effective October 1, 2020, New Code Expected to Expand Reimbursement

GlobeNewsWire - 5 months ago

Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Color...

GlobeNewsWire - 5 months ago

MALVERN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered ...

GlobeNewsWire - 7 months ago

ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers On...

GlobeNewsWire - 7 months ago

MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed o...

Zacks Investment Research - 7 months ago

Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 8 months ago

  ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers

GlobeNewsWire - 8 months ago

Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen Virtual Presentatio...

Zacks Investment Research - 9 months ago

Baudax Bio, Inc. (BXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 9 months ago

MALVERN, Pa., April 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensat...

GlobeNewsWire - 9 months ago

MALVERN, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today ...

GlobeNewsWire - 9 months ago

MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today ...

GlobeNewsWire - 9 months ago

MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today ...

GlobeNewsWire - 10 months ago

Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™ Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™

Seeking Alpha - 10 months ago

Tiny, Underfollowed Baudax Bio Way Too Cheap After Receiving FDA Drug Approval

InvestorPlace - 10 months ago

Baudax Bio (BXRX) news for Friday surrounding approval from the U.S. Food & Drug Administration has BXRX stock taking off.

Seeking Alpha - 10 months ago

Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th.

GlobeNewsWire - 11 months ago

PDUFA Goal Date Set for February 20, 2020 PDUFA Goal Date Set for February 20, 2020

About BXRX

Baudax Bio, a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includ... [Read more...]

Industry
Biotechnology
CEO
Dr. Geraldine A. Henwood
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
BXRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Baudax Bio stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 592.31% from the latest price.

Price Target
$9.00
(592.31% upside)
Analyst Consensus: Buy